Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tapering strategy trial in rheumatoid arthritis remission: csDMARD first versus anti-TNF first
NL-OMON21808Active, not recruiting
- Sponsor
- Erasmus MC, Rotterdam
- Start
- Mar 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of methotrexate in rheumatoid arthritis (RA) (2 arms), sponsored by Erasmus MC, Rotterdam. Primary endpoints: Disease flare in first 12 months, Number of flares in each arm and 1 more. Started Mar 2011; status: active, not recruiting.
02
Drugs
methotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON21808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21808.